1. Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030
- Subjects
Merck KGaA -- Forecasts and trends ,Takeda Pharmaceutical Company Ltd. -- Forecasts and trends ,Novartis Pharma AG -- Forecasts and trends ,Pfizer Inc. -- Forecasts and trends ,Eli Lilly and Co. -- Forecasts and trends ,Brigatinib -- Forecasts and trends -- Reports ,Osimertinib -- Forecasts and trends -- Reports ,Cobimetinib -- Reports -- Forecasts and trends ,Monoclonal antibodies -- Reports -- Forecasts and trends ,Cancer research -- Reports -- Forecasts and trends ,Pembrolizumab -- Forecasts and trends -- Reports ,Epidemiology -- Reports -- Forecasts and trends ,Romiplostim -- Reports -- Forecasts and trends ,Non-small cell lung cancer -- Reports -- Forecasts and trends ,Alectinib -- Forecasts and trends -- Reports ,Durvalumab -- Reports -- Forecasts and trends ,Nivolumab -- Reports -- Forecasts and trends ,Small cell lung cancer -- Forecasts and trends -- Reports ,Pharmaceutical industry -- Forecasts and trends ,Antineoplastic agents -- Reports -- Forecasts and trends ,Market trend/market analysis ,Business ,Business, international - Abstract
M2 PRESSWIRE-July 15, 2020-: Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030 (C)1994-2020 M2 COMMUNICATIONS RDATE:14072020 DelveInsight's 'Non-Small [...]
- Published
- 2020